A 3D virtual model of the PKMYT1–PROTAC–CRBN ternary complex depicting how Insilico Medicine’s bifunctional proteolysis-targeting chimera (PROTAC) D16-M1P2 (shown in yellow) inhibits ...

AI Designs a Novel PROTAC from Scratch: Insilico's generative AI platform, Chemistry42, successfully designed a first-in-class PROTAC targeting PKMYT1 by creating an entirely new inhibitor and its ...

Harbor Freight Tools was hit with a trademark and patent infringement lawsuit on June 26 in Delaware District Court over allegations it copied Streamlight's distinctive 'Ring Mark' design for ...

Reducing the time and expense of engineering PROTAC degraders remains a significant challenge in the pharmaceutical industry. A PROTAC is composed of an E3 ligase ligand (E3-L), a protein of interest ...

Having already stripped back their development plans for the estrogen receptor (ER) degrader vepdegestrant on the back of mixed data, Pfizer and Arvinas have now decided to wash their hands of the ...

As an added bonus, ProTac can be set to a "flicker mode" in which the PDLC continuously (and rapidly) switches back and forth between its transparent and opaque states. This allows the system to ...

Conceptual overview of the vision-based ProTac sensing technology. ProTac can actively switch between proximity and tactile sensing modes, relying on input images captured by inner cameras and a soft ...

CHICAGO -- The investigational oral agent vepdegestrant more than doubled median progression-free survival (PFS) versus fulvestrant (Faslodex) in previously treated estrogen receptor (ER)-positive ...

We may receive a commission on purchases made from links. It shouldn't come as a surprise that Harbor Freight carries a number of good flashlights under different brand names, filling a variety of ...

EAGLEVILLE, PA - Streamlight Inc., a leading provider of high-performance lighting, introduced the ProTac 2.0 HP tactical flashlight, delivering 85,000 candela for powerful downrange illumination, ...

Arvinas, Inc. announced that it will present new preclinical data on its investigational oral PROTAC BCL6 degrader, ARV-393, at the upcoming European Hematology Association (EHA) meeting in Milan from ...